Endothelin receptor activation has been linked to sustained vasoconstriction, a key contributor to renal damage in IgA nephropathy (IgAN). As a result, endothelin receptor antagonists (ERAs) have emerged as a promising therapeutic strategy to slow disease progression, with recent clinical data for new and emerging ERAs showing encouraging outcomes. Tune in to this video and let two leading IgAN experts guide you through this unique drug class and discuss the latest clinical safety and efficacy data for ERAs as novel treatments for IgAN. Through this educational activity, you have the opportunity to earn a maximum of 1.75 CE credits in total. To achieve this, you can complete the PRIME on-demand video to earn 0.5 CE credits. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn an extra 1.25 CE credits. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation. Total Possible Credits: 1.75 CE Credits from PRIME On-Demand Video: 0.5 CE Credits from SynopsiMedEd Related Evidence: 1.25 CE
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/exploring-new-emerging-endothelin-receptor-antagonists-iga-nephropathy
- Start Date: 2024-09-27 05:00:00
- End Date: 2024-09-27 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.75 hours
AMA PRA Category 1 Credit™️: 1.75 hours
Nursing: 1.75 hours
Pharmacy: 1.75 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 12500.0 - Is Kind Support: False Source: Otsuka America Pharmaceutical, Inc. - Amount: 18625.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all